Efficacy of Anlotinib combined with deep-hyperthermia in treating advanced non-small cell lung cancer

CHEN Shuzhi; SUN Qing; HANG Zhiqiang

doi:10.3969/j.issn.1002-7386.2025.06.014

Abstract：Objective To understand the efficacy and safety of Anlotinib combined with deep-hyperthermia in treating advanced non-small cell lung cancer(NSCLC).Methods Sixty patients with advanced NSCLC with disease progression after first-line treatment were randomly assigned into the Trial group(30)and the Control group(30),and all patients were treated with Anlotinib capsules,those in the Trial group were additionally treated with deep-hyperthermia at the chest region.Objective response rate(ORR),disease control rate(DCR)and progression-free survival(PFS)and the occurrence of adverse reactions were included as comparisons between groups.Results ORR(26.7％vs 6.7％),DCR(90.0％vs 66.7％)in the Trial group were significantly higher than those in the Control group(P＜0.05),and the median PFS(9.0 months[95％CI:7.692-10.308]vs 4.0 months[95％CI:2.211-9.789])was significantly longer(P＜0.05).Univariate survival analyses suggested that the presence or absence of deep-hyperthermia was associated with PFS(P＜0.05).While,the COX proportional risk regression model showed that this factor was not an independent prognostic factor for PFS(P=0.051).Adverse reactions in both groups were grades 1-2(Common Terminology Criteria for Adverse Events[CTCAE5.0]),and no grades 3-5 adverse reactions(CTCAE5.0)were observed.Common adverse reactions included skin reactions on hand and foot,cough,shortness of breath,etc.There was no statistical difference in the incidence of common adverse reactions between groups(P＞0.05).Conclusion In the subsequent-line treatment regimens for advanced NSCLC,the combination of Amlotinib and deep-hyperthermia contributes to the improvement of the curve efficacy with manageable adverse effects.